Differences of Interleukin-6 Serum Levels in Lung Cancer Patients and Healthy Individuals in Medan
DOI:
https://doi.org/10.36497/jri.v41i1.155Keywords:
Proinflammatory Cytokine, IL-6, Lung CancerAbstract
Background: Interleukin-6 (IL-6) is a pro-inflammatory cytokines involved in the development of lung cancer. However, the association of IL-6 in lung cancer patients remains uncertain. The aim of this study was to analyze the difference of IL-6 serum levels in lung cancer patients and healthy individuals in Medan. Methods: This was a case-control study that included 42 lung cancer patients (case) and 42 healthy individuals (control) which was held in Haji Adam Malik General Hospital Medan. The examinations of IL-6 serum levels were conducted for all subjects using ELISA method. Differences of IL-6 serum levels in lung cancer patients and healthy individuals were analyzed using Spearman Correlation test. Results: The mean serum IL-6 levels in lung cancer patients was 45.99 pg/ml while in healthy individuals was 6.24 pg/ml. There was a significant difference of serum IL-6 levels in the lung cancer group compared to healthy individuals (P=0.0005;r=0.854). Conclusion: There was a statistically significant difference of IL-6 serum levels between lung cancer patients and healthy individuals.Downloads
References
Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2006; 56:106–30.
Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil): Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: PDPI; 2016. p3.
Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. Cochrane Database Syst Rev. 2004;1:CD001991.
Davalos AR, Coppe JP, Campisi J, Desprez PY. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev. 2010;29(2):273–83.
Seike M, Yanaihara N, Bowman ED, Zanetti KA, Budhu A, Kumamoto K, et al. A cytokine gene signature of the lung adenocarcinoma and its tissue environment predicts prognosis. J Natl Cancer Inst. 2007;99(16):1257–69.
Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A. 2001;98(17):9824–29.
Kaminska J, Kowalska M, Kotowicz B, Fuksiewicz M, Glogowski M, Wojcik E, et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor. Oncology. 2006;70(2):115–25.
Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer. 1995;71(5):1095–8.
Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circu¬lating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22(10):1668–73.
Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002;39(3):149–54.
Takizawa H, Tanaka M, Takami K, Ohtoshi T, Ito K, Satoh M, et al. Increased expression of inflam¬matory mediators in small-airway epithelium from tobacco smokers. Am J Physiol Lung Cell Mol Physiol. 2000;278(5):L906–13.
Tarrant JM. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci.2010.117:4–16.
Cobos C, Figueroa JA, Mirandola L, Colombo M, Summers G, Figueroa A, et al. The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review. Int Rev Immunol.2014. 33:383–401.
Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, et al. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2016;5:e1115942.
Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006;4:221-33.
Jusuf A, Wibawanto A, Icksan AG, Syahruddin E, Juniarti, Endardjo S. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil): Pedoman Diagnosis & Penatalaksanaan di Indonesia. Jakarta: PDPI. 2018. p7.
Ridge C, McErlean A, Ginsberg M. Epidemiology of Lung Cancer. Semin Intervent Radiol. 2013;30(2):93-8.
Margono BP. Kanker Paru. In Wibisono MJ, Winariani, Hariadi S ed. Buku Ajar Ilmu Penyakit Paru 2010. Surabaya: Departemen Ilmu Penyakit Paru UNAIR-RSUD Dr. Soetomo. 2010. p.88-110.
Furrukh M. Tobacco Smoking and Lung Cancer. Sultan Qaboos Univ Med J. 2013;13(3):345-58.
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
